About: http://data.cimple.eu/news-article/affd502b64219fa800bc6cea58ff0961d4b2a0c1a54441e72a1ab852     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • The head of the maker of remdesivir, an anti-viral shown to reduce recovery times in COVID-19 patients, said Sunday the company has been exporting the drug and is making it available to patients in the United States through the US government. Gilead Sciences CEO Daniel O'Day said the company is donating its entire existing supply of the drug -- 1.5 million vials, enough to treat 100,000 to 200,000 patients. "We have been exporting for clinical trials and for compassionate use thousands of treatment courses," O'Day said on CBS's "Face the Nation." "And our collaboration with the government has been such, we have been very transparent with them here in the United States and we have a good relationship on future allocation." US regulators on Friday authorized the experimental drug for emergency use against COVID-19 after a major clinical trial showed it shortened the time to recovery in some coronavirus patients by a third. It is the first medicine to show beneficial results in treating COVID-19 since the new coronavirus emerged in China late last year. O'Day said the US government will determine how the drug is allocated in the United States based on where it is needed most. "They will begin shipping tens of thousands of treatment courses out early this week and adjust that as the epidemic shifts and evolves in different parts and different cities here in the United States," he said. O'Day said there will be a significantly greater supply of remdesivir in the second half of the year. In the meantime, the company has not been barred from exporting the drug, he said. "In terms of the allocation question, I think we're aligned with the US government to both serve the patients here in the United States, and then to be able to also make sure as a global company based in the United States that we can serve other countries," he said. "We've had very good dialogues with the government and that's going well." Remdesivir, which is administered by injection, was already available to some patients who enrolled in clinical trials, or who sought it out on a "compassionate use" basis. The authorization by the federal Food and Drug Administration allows it to be distributed far more widely and used in both adults and children who are hospitalized with a severe form of COVID-19. The FDA defines severe as having low blood oxygen levels, requiring oxygen therapy, or being on a ventilator. jm/bbk
schema:headline
  • Gilead Sciences exporting remdesivir, CEO says
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
http://data.cimple...romotesConspiracy
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software